Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

Study acronym: TOCIACS
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv6 Show 4 more changesShow less
    • Start date changed from estimate of Apr 2025 to Aug 27, 2025
    • Eligibility criteria expanded, about 8 words
    • Site details revised
    • Collaborators expanded, about 5 words
  2. Site contact updatedv5
  3. 2 versions Re-verified since Feb 20, 2025, no change to tracked fieldsv3-v4
  4. Study site revisedv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients with sickle cell disease (SCD) during acute chest syndrome (ACS).
Trial Details
NCT Number NCT06818266
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Conditions
(from sponsor)		 Sickle Cell Disease, Acute Chest Syndrome
Related terms Acute Chest Syndrome, Anemia, Sickle Cell
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov